{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T16:42:58Z","timestamp":1782837778996,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,2,23]],"date-time":"2008-02-23T00:00:00Z","timestamp":1203724800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1007\/s00109-008-0314-6","type":"journal-article","created":{"date-parts":[[2008,2,22]],"date-time":"2008-02-22T08:34:59Z","timestamp":1203669299000},"page":"541-552","source":"Crossref","is-referenced-by-count":24,"title":["Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13"],"prefix":"10.1007","volume":"86","author":[{"given":"Olaf","family":"Merkel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Heyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Asslaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Hamacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Tinhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Holler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"St\u00f6cher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Prokesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Papak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Scheideler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlatko","family":"Trajanoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,2,23]]},"reference":[{"key":"314_CR1","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood-2002-06-1822","volume":"101","author":"S Lanham","year":"2003","unstructured":"Lanham S, Hamblin T, Oscier D, Ibbotson R et al (2003) Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 101:1087\u20131093","journal-title":"Blood"},{"key":"314_CR2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.V99.3.1023","volume":"99","author":"TJ Hamblin","year":"2002","unstructured":"Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z et al (2002) CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99:1023\u20131029","journal-title":"Blood"},{"key":"314_CR3","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1182\/blood-2006-03-010553","volume":"108","author":"I Tinhofer","year":"2006","unstructured":"Tinhofer I, Rubenzer G, Holler C, Hofstaetter E et al (2006) Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. Blood 108:2950\u20132956","journal-title":"Blood"},{"key":"314_CR4","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1182\/blood-2002-06-1683","volume":"100","author":"L Chen","year":"2002","unstructured":"Chen L, Widhopf G, Huynh L, Rassenti L et al (2002) Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 100:4609\u20134614","journal-title":"Blood"},{"key":"314_CR5","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2002-10-3306","volume":"101","author":"A Wiestner","year":"2003","unstructured":"Wiestner A, Rosenwald A, Barry TS, Wright G et al (2003) ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101:4944\u20134951","journal-title":"Blood"},{"issue":"suppl 3","key":"314_CR6","first-page":"X","volume":"28","author":"S Stilgenbauer","year":"2005","unstructured":"Stilgenbauer S, Kr\u00f6ber A, Busch R, Eichhorst B et al (2005) 17p deletion predicts for shorter overall survival after fludarabine-based first line therapy in chronic lymphocytic leukemia: First analysis of the CLL trial of the GCLLSG.. Onkologie 28(suppl 3):X\u2013290:29\u201330","journal-title":"Onkologie"},{"key":"314_CR7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.cdd.4401194","volume":"10","author":"I Sturm","year":"2003","unstructured":"Sturm I, Bosanquet AG, Hermann S, Guner D et al (2003) Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 10:477\u2013484","journal-title":"Cell Death Differ"},{"key":"314_CR8","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","volume":"103","author":"G Lozanski","year":"2004","unstructured":"Lozanski G, Heerema NA, Flinn IW, Smith L et al (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103:3278\u20133281","journal-title":"Blood"},{"key":"314_CR9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2005.03.1021","volume":"24","author":"JC Byrd","year":"2006","unstructured":"Byrd JC, Gribben JG, Peterson BL, Grever MR et al (2006) Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 24:437\u2013443","journal-title":"J Clin Oncol"},{"key":"314_CR10","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","volume":"107","author":"BF Eichhorst","year":"2006","unstructured":"Eichhorst BF, Busch R, Hopfinger G, Pasold R et al (2006) Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885\u2013891","journal-title":"Blood"},{"key":"314_CR11","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","volume":"23","author":"W Wierda","year":"2005","unstructured":"Wierda W, O\u2019Brien S, Wen S, Faderl S et al (2005) Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23:4070\u20134078","journal-title":"J Clin Oncol"},{"key":"314_CR12","first-page":"301","volume":"108","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, Skotnicki A, Robak T, Jaksic B et al (2006) Alemtuzumab (CAMPATH(R), MABCAMPATH(R)) has superior progression free survival (PFS) vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL). ASH Annual Meeting Abstracts 108:301","journal-title":"ASH Annual Meeting Abstracts"},{"key":"314_CR13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","volume":"109","author":"JC Byrd","year":"2007","unstructured":"Byrd JC, Lin TS, Dalton JT, Wu D et al (2007) Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109:399\u2013404","journal-title":"Blood"},{"key":"314_CR14","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2003.01.149","volume":"21","author":"E Raffoux","year":"2003","unstructured":"Raffoux E, Rousselot P, Poupon J, Daniel MT et al (2003) Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 21:2326\u20132334","journal-title":"J Clin Oncol"},{"key":"314_CR15","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJM199811053391901","volume":"339","author":"SL Soignet","year":"1998","unstructured":"Soignet SL, Maslak P, Wang ZG, Jhanwar S et al (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341\u20131348","journal-title":"N Engl J Med"},{"key":"314_CR16","first-page":"155","volume":"5","author":"ZY Shen","year":"2000","unstructured":"Shen ZY, Shen J, Cai WJ, Hong C et al (2000) The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. Int J Mol Med 5:155\u2013158","journal-title":"Int J Mol Med"},{"key":"314_CR17","first-page":"3065","volume":"60","author":"WH Park","year":"2000","unstructured":"Park WH, Seol JG, Kim ES, Hyun JM et al (2000) Arsenic trioxide-mediated growth inhibition in MC\/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 60:3065\u20133071","journal-title":"Cancer Res"},{"key":"314_CR18","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1182\/blood-2002-08-2512","volume":"101","author":"Y Zhou","year":"2003","unstructured":"Zhou Y, Hileman EO, Plunkett W, Keating MJ et al (2003) Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 101:4098\u20134104","journal-title":"Blood"},{"key":"314_CR19","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/sj.leu.2401900","volume":"14","author":"K Kitamura","year":"2000","unstructured":"Kitamura K, Minami Y, Yamamoto K, Akao Y et al (2000) Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia 14:1743\u20131750","journal-title":"Leukemia"},{"key":"314_CR20","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1038\/sj.onc.1208868","volume":"24","author":"C Scholz","year":"2005","unstructured":"Scholz C, Richter A, Lehmann M, Schulze-Osthoff K et al (2005) Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway. Oncogene 24:7031\u20137042","journal-title":"Oncogene"},{"key":"314_CR21","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/sj.onc.1208233","volume":"24","author":"C Scholz","year":"2005","unstructured":"Scholz C, Wieder T, Starck L, Essmann F et al (2005) Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway. Oncogene 24:1904\u20131913","journal-title":"Oncogene"},{"key":"314_CR22","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1182\/blood-2002-10-3231","volume":"101","author":"Q Liu","year":"2003","unstructured":"Liu Q, Hilsenbeck S, Gazitt Y (2003) Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2\/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2\/TRAIL. Blood 101:4078\u20134087","journal-title":"Blood"},{"key":"314_CR23","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M, Kay N et al (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990\u20134997","journal-title":"Blood"},{"key":"314_CR24","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","volume":"348","author":"M Crespo","year":"2003","unstructured":"Crespo M, Bosch F, Villamor N, Bellosillo B et al (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764\u20131775","journal-title":"N Engl J Med"},{"key":"314_CR25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1471-2164-8-70","volume":"8","author":"B Kulterer","year":"2007","unstructured":"Kulterer B, Friedl G, Jandrositz A, Sanchez-Cabo F et al (2007) Gene expression profiling of human mesenchymal stem cells derived from bone marrow during expansion and osteoblast differentiation. BMC Genomics 8:70","journal-title":"BMC Genomics"},{"key":"314_CR26","first-page":"3345","volume":"89","author":"GQ Chen","year":"1997","unstructured":"Chen GQ, Shi XG, Tang W, Xiong SM et al (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 89:3345\u20133353","journal-title":"Blood"},{"key":"314_CR27","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood.V82.11.3452.3452","volume":"82","author":"S Rouby el","year":"1993","unstructured":"el Rouby S, Thomas A, Costin D, Rosenberg CR et al (1993) p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1\/MDR3 gene expression. Blood 82:3452\u20133459","journal-title":"Blood"},{"key":"314_CR28","doi-asserted-by":"crossref","first-page":"37832","DOI":"10.1074\/jbc.M301546200","volume":"278","author":"H Pelicano","year":"2003","unstructured":"Pelicano H, Feng L, Zhou Y, Carew JS et al (2003) Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 278:37832\u201337839","journal-title":"J Biol Chem"},{"key":"314_CR29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cccn.2003.08.013","volume":"338","author":"N Bakan","year":"2003","unstructured":"Bakan N, Taysi S, Yilmaz O, Bakan E et al (2003) Glutathione peroxidase, glutathione reductase, Cu-Zn superoxide dismutase activities, glutathione, nitric oxide, and malondialdehyde concentrations in serum of patients with chronic lymphocytic leukemia. Clin Chim Acta 338:143\u2013149","journal-title":"Clin Chim Acta"},{"key":"314_CR30","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/blood.V93.1.268","volume":"93","author":"J Dai","year":"1999","unstructured":"Dai J, Weinberg RS, Waxman S, Jing Y (1999) Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93:268\u2013277","journal-title":"Blood"},{"key":"314_CR31","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood.V94.6.2102","volume":"94","author":"Y Jing","year":"1999","unstructured":"Jing Y, Dai J, Chalmers-Redman RM, Tatton WG et al (1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94:2102\u20132111","journal-title":"Blood"},{"key":"314_CR32","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/35030140","volume":"407","author":"P Huang","year":"2000","unstructured":"Huang P, Feng L, Oldham EA, Keating MJ et al (2000) Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407:390\u2013395","journal-title":"Nature"},{"key":"314_CR33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/blood-2005-05-1923","volume":"107","author":"JS Carew","year":"2006","unstructured":"Carew JS, Nawrocki ST, Krupnik YV, Dunner K Jr. et al (2006) Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood 107:222\u2013231","journal-title":"Blood"},{"key":"314_CR34","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1124\/jpet.106.103077","volume":"318","author":"BF Taylor","year":"2006","unstructured":"Taylor BF, McNeely SC, Miller HL, Lehmann GM et al (2006) p53 suppression of arsenite-induced mitotic catastrophe is mediated by p21CIP1\/WAF1. J Pharmacol Exp Ther 318:142\u2013151","journal-title":"J Pharmacol Exp Ther"},{"key":"314_CR35","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2007-04-083832","volume":"110","author":"RN Damle","year":"2007","unstructured":"Damle RN, Temburni S, Calissano C, Yancopoulos S et al (2007) CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 110:3352\u20133359","journal-title":"Blood"},{"key":"314_CR36","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1172\/JCI23409","volume":"115","author":"BT Messmer","year":"2005","unstructured":"Messmer BT, Messmer D, Allen SL, Kolitz JE et al (2005) In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 115:755\u2013764","journal-title":"J Clin Invest"},{"key":"314_CR37","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/sj.leu.2403043","volume":"17","author":"JS Carew","year":"2003","unstructured":"Carew JS, Zhou Y, Albitar M, Carew JD et al (2003) Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia 17:1437\u20131447","journal-title":"Leukemia"},{"key":"314_CR38","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.V97.1.256","volume":"97","author":"L Fayad","year":"2001","unstructured":"Fayad L, Keating MJ, Reuben JM, O\u2019Brien S et al (2001) Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 97:256\u2013263","journal-title":"Blood"},{"key":"314_CR39","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/0006-291X(92)91845-H","volume":"182","author":"M Ono","year":"1992","unstructured":"Ono M, Kohda H, Kawaguchi T, Ohhira M et al (1992) Induction of Mn-superoxide dismutase by tumor necrosis factor, interleukin-1 and interleukin-6 in human hepatoma cells. Biochem Biophys Res Commun 182:1100\u20131107","journal-title":"Biochem Biophys Res Commun"},{"key":"314_CR40","doi-asserted-by":"crossref","first-page":"21698","DOI":"10.1074\/jbc.M601083200","volume":"281","author":"SK Dhar","year":"2006","unstructured":"Dhar SK, Xu Y, Chen Y, St Clair DK (2006) Specificity protein 1-dependent p53-mediated suppression of human manganese superoxide dismutase gene expression. J Biol Chem 281:21698\u201321709","journal-title":"J Biol Chem"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-008-0314-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00109-008-0314-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-008-0314-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T05:42:44Z","timestamp":1588398164000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00109-008-0314-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,23]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["314"],"URL":"https:\/\/doi.org\/10.1007\/s00109-008-0314-6","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,23]]}}}